Journal Article

Efficacy and Safety of Pegylated Interferon plus Ribavirin in HIV and Hepatitis C Virus-Coinfected Patients with Advanced Immunosuppression

José A. Mira, Alicia Gutiérrez-Valencia, Gil Ignacio de los Santos, Merino Dolores, Antonio Rivero, María J. Ríos-Villegas, Marcial Delgado, Mercedes González-Serrano, Antonio Collado, Manuel Torres-Tortosa, Mohamed Omar, Miguel Ángel López-Ruz, Juan Macías, Sari Arponen and Juan A. Pineda

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 49, issue 8, pages e84-e91
Published in print October 2009 | ISSN: 1058-4838
Published online October 2009 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/605677
Efficacy and Safety of Pegylated Interferon plus Ribavirin in HIV and Hepatitis C Virus-Coinfected Patients with Advanced Immunosuppression

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background. The aim of this study was to assess the efficacy and safety of pegylated interferon (IFN) plus ribavirin (RBV) in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients with severe immunodeficiency in a clinical cohort.

Methods. A total of 542 HIV-infected patients receiving treatment with pegylated IFN plus RBV from June 2001 through April 2007 were included in this study. The outcome variables were sustained virologic response (SVR) rate and the emergence of AIDS-defining events during HCV infection therapy. SVR rates among patients with a CD4 cell count ⩽250 cells/mm3at baseline were compared with those among patients with CD4 cell counts >250 cells/mm3. The association between SVR and potential predictors was analyzed.

Results. Ten (26%) of 39 individuals with a baseline CD4 cell count ⩽250 cells/mm3and 198 (39%) of 503 with baseline CD4 cell counts >250 CD4 cells/mm3achieved SVR (P=.09). In a nested case-control study with populations matched at a 1:2 ratio, the SVR rate was 26% in the CD4 cell count ⩽250 cells/mm3group and 32% in the CD4 cell count >250 cells/mm3group (P=.5). Baseline CD4 cell count (⩽250 cells/mm3vs >250 cells/mm3) was not associated with SVR in the multivariate analysis. Two (5%) individuals in the CD4 cell count ⩽250 cells/mm3group experienced opportunistic events during follow-up. In the CD4 cell count ⩽250 cells/mm3group, severe hematological toxicity and pegylated IFN or RBV dosage reductions occurred in 16 (41%) and 12 (31%) patients, respectively. In the CD4 cell count >250 cells/mm3group, severe hematological toxicity and pegylated IFN or RBV dosage reductions occurred in 29% (P=.1) and 20% (P=.1) of patients, respectively.

Conclusions. The efficacy of pegylated IFN plus RBV in HIV-HCV-coinfected patients with advanced immunosuppression is substantial and not significantly different to that observed in the overall coinfected population. HCV therapy is generally safe in the population of coinfected patients with advanced immunosuppression.

Journal Article.  4014 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.